Brief Report: Proteasomal Indoleamine 2,3-Dioxygenase Degradation Reduces the Immunosuppressive Potential of Clinical Grade-Mesenchymal Stromal Cells Undergoing Replicative Senescence

Clinical Trials with Mesenchymal Stem Cells: An Update

(2016) Tiziana Squillaro et al.   CELL TRANSPLANTATION

International Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials

(2016) Jacques Galipeau et al.   CYTOTHERAPY

SCFFbxo22-KDM4A targets methylated p53 for degradation and regulates senescence

(2016) Yoshikazu Johmura et al.   Nature Communications

Manufacturing, characterization and control of cell-based medicinal products: challenging paradigms toward commercial use

(2015) Paula Salmikangas et al.   Regenerative Medicine

Senescence-inducing stress promotes proteolysis of phosphoglycerate mutase via ubiquitin ligase Mdm2

(2014) Takumi Mikawa et al.   JOURNAL OF CELL BIOLOGY

IDO-Independent Suppression of T Cell Effector Function by IFN- -Licensed Human Mesenchymal Stromal Cells

(2014) R. Chinnadurai et al.   JOURNAL OF IMMUNOLOGY

Comparison of biological properties of umbilical cord-derived mesenchymal stem cells from early and late passages: Immunomodulatory ability is enhanced in aged cells

(2014) YONG ZHUANG et al.   Molecular Medicine Reports

Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications

(2014) Ying Wang et al.   NATURE IMMUNOLOGY

Fludarabine Downregulates Indoleamine 2,3-Dioxygenase in Tumors via a Proteasome-Mediated Degradation Mechanism

(2014) Laïla-Aïcha Hanafi et al.   PLoS One

Cell Senescence Abrogates the Therapeutic Potential of Human Mesenchymal Stem Cells in the Lethal Endotoxemia Model

(2014) Juan Carlos Sepúlveda et al.   STEM CELLS

Immunological characterization of multipotent mesenchymal stromal cells—The International Society for Cellular Therapy (ISCT) working proposal

(2013) Mauro Krampera et al.   CYTOTHERAPY

The mesenchymal stromal cells dilemma—does a negative phase III trial of random donor mesenchymal stromal cells in steroid-resistant graft-versus-host disease represent a death knell or a bump in the road?

(2013) Jacques Galipeau   CYTOTHERAPY

Clinical-Grade Mesenchymal Stromal Cells Produced Under Various Good Manufacturing Practice Processes Differ in Their Immunomodulatory Properties: Standardization of Immune Quality Controls

(2013) Cedric Menard et al.   STEM CELLS AND DEVELOPMENT

Immunoregulatory properties of clinical grade mesenchymal stromal cells: evidence, uncertainties, and clinical application

(2013) Cédric Ménard et al.   Stem Cell Research & Therapy

Long-Term Complications, Immunologic Effects, and Role of Passage for Outcome in Mesenchymal Stromal Cell Therapy

(2011) Lena von Bahr et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Mesenchymal stromal cell ‘licensing’: a multistep process

(2011) M Krampera   LEUKEMIA

Good Manufacturing Practices Production of Mesenchymal Stem/Stromal Cells

(2010) Luc Sensebé et al.   HUMAN GENE THERAPY

Clinical-grade production of human mesenchymal stromal cells: occurrence of aneuploidy without transformation

(2009) K. Tarte et al.   BLOOD

IFN-γ activation of mesenchymal stem cells for treatment and prevention of graft versus host disease

(2008) David Polchert et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

SOCS3 drives proteasomal degradation of indoleamine 2,3-dioxygenase (IDO) and antagonizes IDO-dependent tolerogenesis

(2008) C. Orabona et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Matrix Metalloproteinase-7 and the 20S Proteasome Contribute to Cellular Senescence

(2008) C. Bertram et al.   Science Signaling